Genetic
SKG0201 Injection
SKG0201 Injection is a genetic therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_1
1
50%
Ph not_applicable
1
50%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 11 (50.0%)
N/A1 (50.0%)
Trials by Status
active_not_recruiting150%
not_yet_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
not_yet_recruitingphase_1
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
NCT07554924
active_not_recruitingnot_applicable
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
NCT06191354
Clinical Trials (2)
Showing 2 of 2 trials
NCT07554924Phase 1
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
NCT06191354Not Applicable
A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1
All 2 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 2